放射性心脏损伤的研究进展  

Research advances of radiation-induced heart disease

作　　者：冯宗健 鄂明艳[1] FENG Zongjian;E Mingyan(Department of Chest Radiotherapy,Cancer Hospital Affiliated to Harbin Medical University,Heilongjiang Harbin 150081,China)

机构地区：[1]哈尔滨医科大学附属肿瘤医院胸部放疗科,黑龙江哈尔滨150081

出　　处：《现代肿瘤医学》2021年第1期159-162,共4页Journal of Modern Oncology

基　　金：海燕基金项目(编号:JJZD2017-07)。

摘　　要：放射治疗作为胸部恶性肿瘤非常重要的局部治疗手段,能够有效地提高局控率及改善患者远期生存。但在放疗过程中,由于解剖位置的因素,心脏作为重要的危及器官不可避免的接受照射,放射相关心脏疾病已成为胸部肿瘤放疗患者非肿瘤性死亡的主要原因之一。因此,放射性心脏损伤(RIHD)在前期临床及基础研究中均已受到越来越广泛的关注,针对RIHD,国内外现已开展多项研究旨在深入探索其发病机制及血清生物标志物,进而早期干预以改善患者的生存质量及临床预后,本文就RIHD的相关研究进行综述。As a key component of local treatment for patients with chest malignant tumors,radiation therapy can effectively improve the local control rate and patients'long-term survival.However,in the process of radiotherapy,due to the anatomic factor,the heart as a vital organ at risk is irradiated inevitably.Radiation-related heart disease had become one of the main non-tumor death causes for patients who received thoracic radiotherapy.Radiation-induced heart disease(RIHD)has received more widespread attention in clinic and basic research.A great number of studies have been carried out to explore the pathogenesis and serum biomarkers,in order to interfere with RIHD as early as possible and then improve patients'quality of life and survival.This article reviewed the development of RIHD.

关 键 词：胸部放射治疗 放射性心脏损伤 血清生物标志物 

分 类 号：R730.6[医药卫生—肿瘤]